2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends
Amgen/Horizon Buyout Lessened Decline
Executive Summary
Even with Amgen’s $27.8bn acquisition of Horizon in mid-December, biopharma M&A volume, total value and average deal value all dropped substantially from 2021.
You may also be interested in...
Despite Pfizer/Seagen’s Splash, Deals Are Staying Small
Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.
Biopharma M&A’s Busy Pace Expected To Continue During 2023’s Second Half
Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at $1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.
Despite Pfizer/Seagen’s Splash, Deals Are Staying Small
Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.